Research

Clinical Trials

Clinical trials are important research studies that explore whether a particular medical strategy or treatment is safe and effective for GIST Cancer patients. These studies also may show which medical approaches work best for treating GIST cancer. The following trials are being held according to eligibility. Click the links for more information.

Oregon Health & Science University

Dr. Michael C. Heinrich

The following clinical trials are currently accepting new participants:

- A Phase 2, Open-Label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults with Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAF or NRAS Mutations

- A Phase 2 Study of CP-868,596 (crenolanib), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Patients with Advanced Gastrointestinal Stromal Tumors with the D842V Mutation in the PDGFRA Gene

- An Open-Label, Randomised, Multi-Centre, Phase 2 Study to Investigate the Safety and Efficacy of AT13387, either as Monotherapy or in Combination with Imatinib, in Patients with Unresectable and/or Metastatic Malignant GIST whose Tumor has Progressed Following Treatment with a Maximum of Three Tyrosine Kinase Inhibitors

- An Open-Label Expanded Access Program of Regorafenib in Patients with Gastrointestinal Stromal Tumors (GIST) After Disease Progression On or Intolerance to Imatinib and Sunitinib
- A Phase 2 Study of OSI-906 in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors

Memorial Sloan Kettering Cancer Center

Dr. Ping Chi & Dr. William Tap

A Phase Ib/II Study of MEK162 in Combination with Imatinib Mesylate in Patients with Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Fox Chase Cancer Center

Dr. Margaret von Mehren

A Study of BLU-285 in Gastrointestinal Stromal Tumors (GIST) and other Solid Tumors.

This is a 2-part study. The first part is a dose-finding part to find the highest dose amount of the study drug with an acceptable level of safety and tolerability.

This part will also look at whether the study drug has any effect on tumors at the doses being used. The second part is an expansion part to check that the chosen dose of the study drug is safe and well tolerated. The part that you are being considered for will depend on which part of the study is open for enrollment.